

INNOVA CAPTAB LIMITED
1281/1, Hilltop Industrial Estate, Near
EPIP, Phase-I, Jharmajri, Baddi, Dist.
Solan (H.P.)-173205 India.
Phone: +91-1795-650820



29th May, 2024

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001
BSE Symbol: INNOVACAP
BSE Scrip Code: 544067

To,
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C/1, “G” Block
Bandra-Kurla Complex
Bandra (E), Mumbai – 400 051
NSE Symbol: INNOVACAP

Dear Sir/Madam,

Subject: Press Release

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, ('SEBI LODR Regulations'), we are enclosing herewith the Press Release issued by the Company on the Audited Financial Results (Standalone and Consolidated) for the quarter and financial year ended 31st March, 2024.

The Press Release is available on the website of the Company at www.innovacaptab.com

This is for your information and record.

Thanking you,

Yours faithfully,
For **Innova Captab Limited**

Neeharika Shukla
Company Secretary & Compliance Officer
Membership No.: A42724

Encl.: As above



INNOVA CAPTAB LIMITED

PRESS RELEASE

Performance Review of Q4 & FY24

Innova Captab Limited reported a strong set of numbers for FY 24 with Revenue from Operations at ₹1,081.31 crore and Profit After Tax at ₹ 94.35 crore

Mumbai: 29th May 2024: Innova Captab Limited (BSE: 544067, NSE: INNOVACAP) is an integrated pharmaceutical company in India with a presence across the pharmaceuticals value chain including research and development, manufacturing, drug distribution and marketing and exports has announced its financial results for the last quarter and full year ended March 31st, 2024

Financial Performance: FY24 v/s FY23

- Total Income for the FY 24 stood at ₹ **1,093.79 Crore** against ₹ **935.58 Crore** in FY 23 with growth of **16.9%** over FY 23.
- Revenue from Operation has increased to ₹ **1,081.31 Crore** in FY 24 from ₹ **926.38 Crore** in FY 23, registering a growth of **16.7%**.
- The Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) stands at ₹ **166.94 Crore** in FY24, as against ₹ **122.85 Crore** in FY 23, with an increase of **35.9%**.
- Profit After Tax (PAT) is ₹ **94.35 Crore** in FY 24 as against ₹ **67.95 Crore** in FY 23, registering a growth of **38.9%**.
- Earnings per share (EPS) for FY 24 is ₹ **18.66**, against ₹ **14.16** in FY 23
- For FY24, net cash generated from operating activities stood at ₹ **146 Crore**, against ₹ **67 Crore** in FY 23.

Financial Performance: Q4FY24 v/s Q4FY23

- Revenue from operation is ₹ **262.63 Crore** in Q4 FY24 as against ₹ **240.95 Crore** of previous year registering a growth of **9.0%**.
- The Company's EBITDA stood at ₹ **43.76 Crore** in Q4 FY24 against ₹ **29.42 Crore** of previous year registering a growth of **48.7%**.
- Profit After Tax (PAT) stood at ₹ **28.72 Crore** in Q4 FY24 against ₹ **17.25 Crore** of previous year registering a growth of **66.5%**.

Commenting on the results, **Vinay Lohariwala, Managing Director, - Innova Captab Limited** said, For FY24, we reported a total income of ₹ **1,094 crore** with a growth of **16.9%** compared to the previous year. Our all business areas are getting good traction and are expected to grow at a healthy rate in the coming years.

Over the last 3-4 years, we have grown at a healthy rate of ~ 20% CAGR. With our upcoming Jammu facility and recent Sharon acquisition, we are positively looking forward to maintaining the same healthy growth rate over the next 3-4 years.

As a company we continue to drive sustainable growth by exploring new opportunities and focusing on value-added products. Indian pharmaceutical companies are set to experience significant growth in the mid to long term, as both domestic and global manufacturers seek reliable and sustainable suppliers like us.

About Innova Captab Ltd : <https://www.innovacaptab.com> :

The foundation of Innova is their in-house research and development which helps to focus on building complex product portfolio. As a major CDMO player, Innova caters to India's top 14 out of 15 pharmaceuticals companies and have license to manufacture products through four state of the art manufacturing facilities at Baddi - Himachal Pradesh, Dehradun - Uttarakhand and at Taloja - Maharashtra while maintaining WHO-GMP, EU-GMP, UK-MHRA and other major registrations with these facilities.

By Q2'FY25, the upcoming greenfield plant in Jammu is expected to be commercialized and commence operations in all the four blocks i.e cephalosporin, penicillin, penum and BFS to manufacture oral solid dosages, dry powder injections, dry syrup, BFS and respiratory respule products.

With the acquisition of Sharon in June'23, Innova aims to create long-term synergy with additional product offerings like formulations and APIs.

For more information, contact:

Mr. Lokesh Bhasin
Email : investors@innovacaptab.com
www.innovacaptab.com

DISCLAIMER:

Certain statements that are made in the Press Release may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like significant changes in the economic environment in India and overseas, tax laws, inflation, litigation, etc. Actual results might differ substantially from those expressed or implied. Innova Captab Ltd. will not be in any way responsible for any action taken based on such statements and discussions; and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.